 

IV 





It is further ordered 

that RN Nutrition, a limited partnership, and George Page Rank and James W. Nugent, individually and as co-partners,
trading and doing business as RN Nutrition, or under any other name, their successors and assigns, and respondents'
agents, representatives, and employees, directly or through any partnership, corporation, subsidiary, division
or other device, in connection with the labeling, advertising, promotion, offering for sale, sale, or distribution
of BoneRestore or any food or dietary supplement, food, or drug, as ``food'' and ``drug'' are defined in section 15
of the Federal Trade Commission Act, in or affecting commerce, as ``commerce'' is defined in the Federal Trade Commission
Act, do forthwith cease and desist from misrepresenting, in any manner, directly or by implication, the existence,
contents, validity, results, conclusions, or interpretations of any test or study. 



V 





It is further ordered 

that RN Nutrition, a limited partnership, and George Page Rank and James W. Nugent, individually and as co-partners,
trading and doing business as RN Nutrition, or under any other name, their successors and assigns, and respondents'
agents, representatives, and employees, directly or through any partnership, corporation, subsidiary, division
or other device, in connection with the labeling, advertising, promotion, offering for sale, sale, or distribution
of BoneRestore or any food or dietary supplement, food, or drug, as ``food'' and ``drug'' are defined in section 15
of the Federal Trade Commission Act, in or affecting commerce, as ``commerce'' is defined in the Federal Trade Commission
Act, do forthwith cease and desist from making any representation, in any manner, directly or by implication, that
any such product will treat, cure, alleviate the symptoms, prevent, or reduce the risk of developing any disease,
disorder, or condition, unless, at the time of making such representation, respondents possess and rely upon competent
and reliable scientific evidence that substantiates the representation. 



VI 



Nothing in this Order shall prohibit respondents from making any representation that is specifically permitted
in labeling for any such product by regulations promulgated by the Food and Drug Administration pursuant to the Nutrition
Labeling and Education Act of 1990. 



VII 



Nothing in this Order shall prohibit respondents from making any representation for any drug that is permitted in
labeling for any such drug under any tentative final or final standard promulgated by the Food and Drug Administration,
or under any new drug application approved by the Food and Drug Administration. 



VIII 





It is further ordered 

that for five (5) years after the last date of dissemination of any representation covered by this Order, respondents,
or their successors and assigns, shall maintain and upon request make available to the Federal Trade Commission for
inspection and copying: 

A. All materials that were relied upon in disseminating such representation; and 

B. All tests, reports, studies, surveys, demonstrations or other evidence in their possession or control that contradict,
qualify, or call into question such representation, or the basis relied upon for such representation, including
complaints from consumers. 



